Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
Aligos Therapeutics, Inc. (ALGS) will report its Q4 2023 financial results on March 12, 2024, focusing on liver and viral disease therapeutics.
03/05/2024 - 04:05 PM
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s fourth quarter 2023 financial results on Tuesday, March 12, 2024, after the close of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as chronic hepatitis B (CHB) and coronaviruses.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, and the impact of global events and other macroeconomic conditions on the Aligos business. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2023 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Company Jordyn Tarazi Vice President, Investor Relations & Corporate Communications (650) 910-0427jtarazi@Aligos.com
Media Veronica Eames LifeSci Communicationsveames@lifescicomms.com
When will Aligos Therapeutics report its Q4 2023 financial results?
Aligos Therapeutics will report its Q4 2023 financial results on March 12, 2024.
What is Aligos Therapeutics' ticker symbol?
Aligos Therapeutics' ticker symbol is ALGS.
What is the focus of Aligos Therapeutics' therapeutics development?
Aligos Therapeutics focuses on developing novel therapeutics for liver and viral diseases.
ALGS Rankings
#4378 Ranked by Stock Gains
ALGS Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major
About ALGS
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-ã agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.